Review article: β3-adrenoceptor agonists - Future anti-inflammatory drugs for the gastrointestinal tract?

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 859-863

  Anthony, A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; [[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD FLOW; DRUG MECHANISM; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STOMACH ULCER;

EID: 0029824505     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.71245000.x     Document Type: Review

References (45)

1. Lands AM, Arnold A, McAuliffe JP, et al. Differentiation of receptor systems activated by sympathomimetic compounds. Nature 1967; 214: 597-8.
2. Harms HH, Zaagsma J, van der Wal B. Beta-adrenoceptor studies. III. On the beta-adrenoceptors in rat adipose tissue. Eur J Pharmacol 1974; 25: 87-91.
3. Tan S, Curtis-Prior PB. Characterization of the adipose tissue of the rat. Int J Obesity 1983; 7: 409-14.
4. Wilson C, Wilson S, Piercy V, et al. The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists. Eur J Pharmacol 1984; 100: 309-19.
5. Arch JRS, Ainsworth AT, Cawthorne MA, et al. Atypical beta-adrenoceptors on brown adipocytes as targets for anti-obesity drugs. Nature 1984; 309: 163-5.
6. 3-adrenoceptor. Science 1989; 245: 1118-21.
7. 3 and atypical adrenoceptors. Med Res Rev 1993; 13: 663-729.
8. 3-adrenoceptor agonists. Drugs Future 1993; 18: 529-49.
9. 3-selective adrenoceptor antagonist, SR 59230A. Br J Pharmacol 1996; 117: 1374-76.
10. MacDonald A, Forbes IJ, Gallacher D, et al. Adrenoceptors mediating relaxation to catecholamines in rat isolated jejunum. Br J Pharmacol 1994; 112: 576-8.
11. 3-adrenoceptors. Br J Pharmacol 1995; 116: 1945-7.
12. 3 receptor. J Pharmacol Exp Ther 1995; 272: 446-51.
13. Bianchetti A, Manara L. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical β-adrenoceptors in rat colon. Br J Pharmacol 1990; 100: 831-9.
14. Canfield P, Abdul-Ghaffar T. Stimulation of bicarbonate secretion by atypical β receptor agonists in rat caecum in vitro. Eur J Pharmacol 1992; 216: 218-26.
15. Koike K, Horinouchi T, Takayanagi I. Possible mechanisms of β-adrenoceptor-mediated relaxation induced by noradrenaline in guinae pig taenia caecum. Eur J Pharmacol 1995; 279: 159-63.
16. 3-adrenoceptors. Br J Pharmacol 1995; 114: 1447-53.
17. 3-adrenoceptor gene. Mol Pharmacol 1993: 44: 264-70.
18. 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 1995; 289: 223-8.
19. 3-adrenergic receptor mRNA in man. J Clin Invest 1993; 91: 344-9.
20. 3-adrenergic receptor. Mol Pharmacol 1991; 40: 895-9.
21. Roberts SJ, Russell FD, Molenaar P, et al. Characterisation and localisation of atypical β-adrenoceptors in rat ileum. Br J Pharmacol 1995; 116: 2549-56.
22. Summers RJ, Russell FD, Roberts SJ, et al. Localisation and characterization of atypical β-adrenoceptors in skeletal muscle and gut. Pharmacol Commun 1995; 6: 237-52.
23. 3-adrenergic receptor. Eur J Biochem 1995; 224: 761-70.
24. Berlan M, Galitzky J, Bousquet-Melou A, et al. Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther 1994; 268: 1444-51.
25. Shen Y-T, Zhang H, Vatner SF. Peripheral vascular effects of beta-3 adrenoceptor stimulation in concious dogs. J Pharmacol Exp Ther 1994; 268: 466-73.
26. 3-adrenoceptor agonist induces increased pancreatic blood flow and insulin secretion in rats. Eur J Pharmacol 1996; 298: 287-92.
27. Takahashi H, Yoshida T, Nishimura M, et al. Beta-3 adrenergic agonist, BRL-26830A, and alpha/beta blocker, arotinolol, markedly increase regional blood flow in the brown adipose tissue in anaesthetised rats. Jpn Circ J 1992; 56: 936-42.
28. Kuratani K, Yamazaki M, Kodama H, et al. Possible involvement of hyperinsulinaemia and adrenergic activation in the pathogenesis of indomethacin-induced antral ulcers in non-fasted hamsters and refed rats. J Pharmacol Exp Ther 1992; 263: 951-5.
29. Howard TJ. Passaro E, Guth PH. Isoprotenerol prevents ethanol-induced microvascular stasis and deep histological injury in rat gastric mucosa. Dig Dis Sci 1993; 38: 1201-9.
30. Kuratani K, Kodama H, Yamaguchi I. Enhancement of mucosal blood flow by beta-3 adrenergic agonists prevents indomethacin-induced antral ulceration in the rat. J Pharmacol Exp Ther 1994; 270: 559-65.
31. 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat. Br J Pharmacol 1996; 117: 580-6.
32. Tackeuchi K, Okada M, Ebara S, et al. Inceased microvascular permiability and lesion formation during gastric hypermotility caused by indomethacin and 2-deoxy-D-glucose in the rat. J Clin Gastroenterol 1990; 12 (Suppl. 1): S76-84.
33. Livingstone EH, Howard TJ, Garrick TH, et al. Strong gastric contractions cause mucosal ischaemia. Am J Physiol 1991; 260: G524-30.
34. Anthony A, Dhillon AP, Nygard G, et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther 1993; 7: 29-40.
35. Nygard G, Anthony A, Piasecki C, et al. Acute indomethacin-induced injury in the rat: early morphological and biochemical changes. Gastroenterology 1994: 106: 567-75.
36. Anthony A, Dhillon AP, Thrasivoulou C, et al. Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum: a detailed morphological study. Aliment Pharmacol Ther 1995; 9: 605-13.
37. Kelly D, Piasecki C, Anthony A, et al. Early indomethacin lesions in rat jejunum: reduced focal blood flow and shortening of villi precede ulceration. Gut 1996; 38 (Suppl. 1): A60(Abstract).
38. 3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening. J Pathol 1996; 179: 340-6.
39. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal granulomatous infarction. Lancet 1989; ii: 1057-62.
40. Goulston SJM, McGovern VJ. The nature of benign strictures in ulcerative colitis. N Engl J Med 1969: 281: 290-5.
41. Bjamason I, Zanelli G, Smith T, et al. Non-steroidal anti-inflammatory drug induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480-9.
42. Allison MC, Howatson AG, Torrance CJ. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749-54.
43. Takala J, Splanchnic blood flow and multiple organ failure. Br J Hosp Med 1995; 54: 485-7.
44. Maynard N, Bihari D, Beale R, et al. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. J Am Med Assoc 1993; 270: 1203-10.
45. Beeby PJ, Jeffery H. Risk factors for necrotising enterocolitis: The influence of gestational age. Arch Dis Child 1992; 67: 432-5.